PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514942
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1514942
Antibody Drug Conjugates Market size was valued at USD 8,954.2 Million in 2023, expanding at a CAGR of 11.50% from 2024 to 2032.
Antibody-drug conjugates (ADCs) are a type of targeted therapy that selectively delivers strong cytotoxic medicines to cancer cells. They consist of three major components: a monoclonal antibody, a cytotoxic payload, along with a linker molecule. ADCs bring the cytotoxic payload directly to cancer cells while causing minimal damage to healthy cells, boosting efficacy and lowering systemic toxicity associated with conventional chemotherapy. ADCs, with their particular targeting and payload delivery mechanisms, are a potential option in cancer treatment.
Antibody Drug Conjugates Market- Market Dynamics
Growing Number of Clinical Trial Studies is Expected to Fuel the Market Growth
The increasing number of clinical trial studies is projected to drive the antibody drug conjugates market in the future. A clinical trial is a research study in which people volunteer to try new treatments, interventions, or tests in order to prevent, detect, treat, or manage various diseases or medical conditions. Antibody-drug conjugates have emerged as an important category of anti-cancer drugs, with a fast-increasing number of antibody-drug conjugates entering clinical trials for the treatment of blood-related malignancies and solid tumors. For instance, according to The Talks, a Canada-based provider of advertising services, there were 452,604 registered clinical trials on ClinicalTrials.gov in May 2023, a significant increase from the approximately 365,000 trials recorded in early 2021.
Antibody Drug Conjugates Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.50% over the forecast period (2024-2032)
Based on product type segmentation, in 2023, the Kadcyla sector generated the largest revenue in the ADC sector.
Based on Technology segmentation, the cleavable linker sector had the biggest revenue share in 2023.
Based on Application segmentation, breast cancer segment dominated the market in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Antibody Drug Conjugates Market is segmented on the basis of Product Type, Technology, Application, Target Type, and Region.
The market is divided into four categories based on product type: Adcetris, Perjeta, Kadcyla, and Other product types. The Kadcyla segment generated the most revenue in the ADC area in 2023. The rise in breast cancer cases, combined with increased approvals for ADCs designed specifically for breast cancer treatment, pulls the market forward. F. Hoffmann-La Roche Ltd. announced clearance for Kadcyla in China's rapidly developing sector in January 2022, marking a watershed moment.
The market is divided into three categories based on Technology: Cleavable Linker, Non-cleavable Linker, and Linkerless. The cleavable linker sector had the highest revenue share in 2023. The capacity of cleavable linkers to remain stable in the bloodstream for extended periods of time and to release cytotoxins from ADCs makes them the most widely employed technology for achieving an effective outcome of ADCs in cancer therapy.
Antibody Drug Conjugates Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The North American antibody drug conjugate market had the most revenue share in 2023. Increased awareness of ADCs among healthcare professionals, combined with advantageous reimbursement rules, is driving market expansion. North America is predicted to experience considerable growth throughout the projection period because of greater awareness of current treatment methods, attractive reimbursement rules, significant R&D expenditure, and improved patient affordability. Seagen, Inc., F. Hoffmann La-Roche Ltd., Gilead Sciences Inc., and Pfizer Inc. are among the prominent businesses active in this region.
The Asia Pacific antibody, drug conjugates market, is the region that grows at the fastest CAGR over the forecast period. Rising cancer cases and a growing senior population in the region are expected to drive growth in the Asia Pacific antibody drug conjugates market. Furthermore, the rising incidences of lung, ovarian, and stomach cancer in China and India have compelled researchers to develop sophisticated cancer treatment alternatives in order to reduce mortality. In recent years, Asia Pacific's healthcare system has embraced antibody-drug conjugates as an effective cancer treatment. Throughout the projected period, demand for antibody-drug conjugates in Asia Pacific is expected to be stable.
The competitive landscape of the Antibody Drug Conjugates Market has altered, and it is being fueled further by the growing need for sophisticated medicines in oncology and, increasingly, in other disease areas. Takeda Pharmaceutical Company Limited, Pfizer Inc, GlaxoSmithKline Plc, AstraZeneca, and Seagen Inc are key participants in this market, competing on the basis of the development of innovative ADCs with enhanced efficacy and safety profiles. Companies rely on strategic alliances, acquisitions, and clinical collaborations to strengthen and widen the reach of their product portfolios. The development of novel antibody-drug conjugates is a defining feature of the competitive research and development scene.
In April 2023, Innate Pharma and Takeda Pharmaceutical Company Ltd inked an agreement to conduct research and development of antibody-drug conjugates (ADCs), with a primary focus on celiac disease. This method is expected to help Takeda gain global exclusive rights to employ a set of selected Innate antibodies to produce, manufacture, and commercialize the ADCs.
GLOBAL ANTIBODY DRUG CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Takeda Pharmaceutical Company Limited
Pfizer Inc
GlaxoSmithKline Plc
AstraZeneca
Seagen Inc
ADC Therapeutics
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
Others